Lifileucel not checked
Iovance Biotherapeutics, Inc. · LN-145 · LN - 144
FollowEvery change as it happens, and a Monday email
Trials
5 active
9 in total · 5 in the EU
Targets
—
None known yet
What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.”In the company’s words, NCT05727904 on ClinicalTrials.gov
- Tested for
- Metastatic Melanoma (2 trials), Unresectable Melanoma (2 trials), Melanoma, Melanoma (Skin Cancer), Endometrial Cancer, Metastatic Non Small Cell Lung Cancer, Sarcoma, Soft Tissue Sarcoma (STS) and 3 more
- Main trialPhase 3
- “This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.”In the company’s words, NCT05727904 on ClinicalTrials.gov
- Other names
- LN-145 · Tumor-Infiltrating Lymphocytes · TIL · LN - 144
Other drugs for Metastatic Melanoma
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up5
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- May 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2030Phase 2 trial completes · ClinicalTrials.gov
- 1 Sep 2033Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Mar 2028 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | |
| Phase 2Active, not recruiting | Dec 2027 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma | |
| Phase 2Recruiting | May 2028 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | |
| Phase 2Recruiting | Dec 2030 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | |
| Phase 2Recruiting | 1 Sep 2033 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma | |
| Phase 2Completed | 8 Aug 2022 | Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | |
| Phase 2Completed | 24 Oct 2024 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | |
| Phase 2Terminated | 22 Aug 2025 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma | |
| Phase 2Terminated | 20 Feb 2026 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026